Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC)

Groupe Francais De Pneumo-Cancerologie

Status: Completed

Conditions: Neuroendocrine Carcinoma of Lung (Diagnosis); Large Cell Lung Cancer

Treatments: Other: Immunohistochemistry

Study type: Observational

Funder types: Other

Identifiers

NCT03305133

GFPC 03-2017

Details and patient eligibility

About

Observational, multicentre, retrospective study on patients taken care according to the national guidelines. The objective is to define, after the diagnosis confirmation, the frequency of PD-L1 expression in patients with large-cell lung neuroendocrine carcinoma (NEC), whatever the stage of the disease, and to correlate this parameter to clinical data at the time of diagnosis, therapeutic response and survival. Large-cell NECs present a bad prognostic and there is no evidence of treatment for these patients with advanced disease in second ligne of treatment at that time. To demonstrate the PD-L1 expression in this type of cancer might have a major therapeutic impact in a close future to access immunotherapies.

Enrollment: 86 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged > or = 18 years
• Diagnosis of Large-cell NEC confirmed by centralised reading
• Tumoral materials available and readable for PD-L1 labeling

Exclusion criteria

• Other type of Lung cancers
• Tumoral material not available or not readable for centralised reading
• Tumoral material not available or not readable for PD-L1 labeling